Net sales / Income from operations at Rs. 3,927 crores, a growth of 13% over same quarter last year. |
Sun Pharmaceutical Industries Ltd reported financials for first quarter ending June 30th, 2014.
Net sales / Income from operations at Rs. 3,927 crores, a growth of 13% over same quarter last year.
Branded generic sales in India at Rs. 992 crores, up by 17% over Q1 last year.
US finished dosage sales at US$ 389 million grew by 7% (in US$ terms) over Q1 last year.
International formulation sales outside US at US$ 82 million, grew by 2% (in US$ terms) over Q1 last year.
Overall international revenues accounted for more than 75% of total revenues for the quarter.
EBITDA at Rs. 1,724 crores grew by 13%; resulting EBITDA margin of 44%, same as Q1 last year.
Adjusted Net profit at Rs 1,391 crores witnessed a growth of 12% over Q1 last year; resulting margin of 35%.
Reported Net profit at Rs. 1,391 crores, compared to Net loss of Rs. 1,276 in Q1 last year. The loss in Q1 last year was on account of a provision of Rs. 2,517 crores towards settlement for patent infringement litigation related to generic versions of ‘Protonix’.
These results were taken on record by the Board of Directors at a meeting held in Mumbai today.
No comments:
Post a Comment